| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/18/2002 | WO2001068570A3 Il-8 receptor antagonists |
| 04/18/2002 | WO2001068569A3 Il-8 receptor antagonists |
| 04/18/2002 | WO2001068075A3 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 04/18/2002 | WO2001066595A3 Human fgf-23 gene and gene expression products |
| 04/18/2002 | WO2001064681A3 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 04/18/2002 | WO2001060400A3 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 04/18/2002 | WO2001060378A3 Antiadhesive carbohydrates |
| 04/18/2002 | WO2001060345A3 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator |
| 04/18/2002 | WO2001058893A3 Indol-3-yl derivatives and their use as integrin inhibitors |
| 04/18/2002 | WO2001055101A3 A new process for the preparation of latanoprost |
| 04/18/2002 | WO2001051520A3 Nogo receptor-mediated blockade of axonal growth |
| 04/18/2002 | WO2001045691A3 Method of treating gastrointestinal tract disease with purinergic receptor agonists |
| 04/18/2002 | WO2001034202A3 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells |
| 04/18/2002 | WO2001026656A3 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors |
| 04/18/2002 | WO2001026644A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 04/18/2002 | WO2001025437A3 Growth factor polypeptides and nucleic acids encoding same |
| 04/18/2002 | WO2000075184A9 Modulation of protein levels using the scf complex |
| 04/18/2002 | WO2000073482A9 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders |
| 04/18/2002 | WO2000072856A9 Fibrin sealants providing less inflammatory response and methods using same |
| 04/18/2002 | WO2000070341A9 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 04/18/2002 | WO2000068387A9 Nucleic acids and proteins with interferon-beta activity |
| 04/18/2002 | WO2000068385A9 Novel nucleic acids and proteins with growth hormone activity |
| 04/18/2002 | US20020045765 Tocopherol derivatives and method for preparation thereof |
| 04/18/2002 | US20020045761 Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them |
| 04/18/2002 | US20020045665 Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 04/18/2002 | US20020045663 Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine |
| 04/18/2002 | US20020045656 NMDA receptor NR2B subunit antagonist and a neutrophil inhibiting factor; therapies that reduce or prevent neuronal dysfunction and death after ischemic, hypoxic or traumatic CNS insult |
| 04/18/2002 | US20020045650 Substituted indole proteolytic enzyme inhibitors as cancer treating agents |
| 04/18/2002 | US20020045648 Therapeutic compositions comprising excess enantiomer |
| 04/18/2002 | US20020045645 Lactone integrin antagonists |
| 04/18/2002 | US20020045642 Antiinflammatory, -arthritic and -emetic agents; central nervous system disorders; Parkinson's disease; antidepressants; psychological disorders; anxiolytic agents; antagonists of substance P receptors |
| 04/18/2002 | US20020045638 Method of treating estrogen receptor positive carcinoma |
| 04/18/2002 | US20020045630 Antiproliferative, -carcinogenic, -tumor and -diabetic agents; binding to or modulating the human kinase insert-domain-containing receptor (KDR) or the murine fetal liver kinase 1 (FLK-1) receptor; vasculogenesis; angiogenesis |
| 04/18/2002 | US20020045629 Sleep, eating and brain disorders, wakefulness promoters; Parkinson's disease, antiischemic agents, stroke, chronic fatigue syndrome; antidepressants; schizophrenia, nervous system disorders; multiple sclerosis, cognition activators |
| 04/18/2002 | US20020045625 Oxazolidinone chemotherapeutic agents |
| 04/18/2002 | US20020045623 Stable; potent; penetrates cell membranes; effectively hinders cellular apoptosis; Antiinflammatory agents, Ischemic agents, cancer, autoimmune diseases and nervous system disorders. |
| 04/18/2002 | US20020045621 A mobile ionophore composition effective to modulate APP catabolism without substantially altering the viability of APP-containing cells; inhibits amyloid deposition; Alzheimer's disease; nontoxic |
| 04/18/2002 | US20020045619 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents |
| 04/18/2002 | US20020045616 Lactam inhibitors of FXa and method |
| 04/18/2002 | US20020045614 1-(4-(((4-Amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino) methyl)-4-phenyl-piperidin-1-yl)-1-cyclopropyl-methanone; treating disease states ameliorated by blockade of alpha-1 adrenoceptors; sleep/psychological disorders |
| 04/18/2002 | US20020045613 1-aroyl-piperidinyl benzamidines |
| 04/18/2002 | US20020045608 Drug addiction, drug dependence |
| 04/18/2002 | US20020045603 Method of inhibiting membrane-type matrix metalloproteinase |
| 04/18/2002 | US20020045597 N-acylated-2-glucosamine derivatives for treating osteoarthritis/inflammatory arthritis, and enhancing cartilage formulation, chondrocyte cell proliferation and glycosaminoglycan production |
| 04/18/2002 | US20020045595 N6 heterocyclic 8-modified adenosine derivatives |
| 04/18/2002 | US20020045593 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons |
| 04/18/2002 | US20020045575 Treating inflammatory, autoimmune diseases, including graft-versus-host disease and enhancement of graft/tissue survival following transplant |
| 04/18/2002 | US20020045573 Dithiocarbamates linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein); treating cerebral stroke and other ischemia/reperfusion injury |
| 04/18/2002 | US20020045566 Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 04/18/2002 | US20020045264 Expression vectors for use in gene therapy |
| 04/18/2002 | US20020045214 Rat G-protein coupled receptor AXOR29 |
| 04/18/2002 | US20020045206 Contacting the cells with a trophic amount of a ptc therapeutic for promoting survival of substantia nigra neuronal cells |
| 04/18/2002 | US20020045203 Method for detecting active ingredients of medical value |
| 04/18/2002 | US20020045166 Peptides; for use as tools in gene therapy |
| 04/18/2002 | US20020044981 Mixture of polyunsaturated fatty acids containing linoleic, gamma-linolenic, alpha-linolenic, and stearidonic acid; antilipemic agent, antioxidant and/or antidiabetic agent. |
| 04/18/2002 | US20020044977 Centipeda plant extract |
| 04/18/2002 | DE10050994A1 New diphenylalkanoic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease |
| 04/18/2002 | DE10050663A1 Use of amino-substituted imidazo(1,2-a)pyridine, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine derivatives as NO synthase inhibitors, e.g. in treatment of migraine and neurodegenerative diseases |
| 04/18/2002 | CA2765409A1 Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
| 04/18/2002 | CA2459746A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
| 04/18/2002 | CA2427499A1 Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents |
| 04/18/2002 | CA2425910A1 Treatment and prevention of gastrointestinal disease using antagonists or partial agonists of 5ht1a receptors |
| 04/18/2002 | CA2425835A1 Methods and compositions for nucleic acid delivery |
| 04/18/2002 | CA2425815A1 Treatment of t cell disorders |
| 04/18/2002 | CA2425771A1 Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 04/18/2002 | CA2425765A1 Novel drugs for liver diseases |
| 04/18/2002 | CA2425674A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425672A1 Use of substituted imidazo[1,2-a]-pyridin-,pyrimidin-and -pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting nos |
| 04/18/2002 | CA2425632A1 Agents for the treatment of viral infections |
| 04/18/2002 | CA2425581A1 Modulation of ligand binding/enzymatic activity of alpha beta proteins |
| 04/18/2002 | CA2425520A1 N-alkylglycine trimeres capable of blocking the response to chemical substances, heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres |
| 04/18/2002 | CA2425508A1 Targeted therapeutic agents |
| 04/18/2002 | CA2425416A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and methods for preparing same |
| 04/18/2002 | CA2425359A1 Dioxolane analogs for improved inter-cellular delivery |
| 04/18/2002 | CA2425356A1 Hedgehog antagonists, methods and uses related thereto |
| 04/18/2002 | CA2425298A1 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof |
| 04/18/2002 | CA2425001A1 Novel serine protease genes related to dppiv |
| 04/18/2002 | CA2424983A1 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | CA2424971A1 Topoisomerase inhibitors |
| 04/18/2002 | CA2424951A1 Beta-amino acid derivatives as integrin receptor antagonists |
| 04/18/2002 | CA2424821A1 Gene encoding a human g-protein coupled receptor and its use |
| 04/18/2002 | CA2424802A1 Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same |
| 04/18/2002 | CA2424438A1 Anhydro sugar derivatives of indolocarbazoles |
| 04/18/2002 | CA2424299A1 Combination therapy for the treatment of estrogen-sensitive disease |
| 04/18/2002 | CA2424292A1 Tricyclic compounds and uses thereof |
| 04/18/2002 | CA2423595A1 Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery |
| 04/18/2002 | CA2422744A1 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| 04/18/2002 | CA2422718A1 Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins |
| 04/18/2002 | CA2394084A1 Inhibitors of protein kinases |
| 04/17/2002 | EP1197496A1 Novel peptides |
| 04/17/2002 | EP1197488A1 (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use |
| 04/17/2002 | EP1197484A2 1H-Indole-3-glyoxylamide sPLA2 inhibitors |
| 04/17/2002 | EP1197226A1 Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| 04/17/2002 | EP1197220A2 Therapeutic methods and compositions based on delta proteins and nucleic acids |
| 04/17/2002 | EP1197218A1 Algae protein polysaccharide extraction and use thereof |
| 04/17/2002 | EP1197213A2 Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis |
| 04/17/2002 | EP1196783A2 Screening for therapeutic agents being scap antagonists |
| 04/17/2002 | EP1196772A2 Induction of a th1-like response in vitro |
| 04/17/2002 | EP1196638A1 USE OF THE i KRIT1 /i GENE IN ANGIOGENESIS |
| 04/17/2002 | EP1196635A2 Cell death related drug targets in yeast and fungi |